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Abstract
Accumulating evidence(s) indicate that CXCL12-CXCR4 signaling cascade plays an important role in the process of invasion
and metastasis that accounts for more than 80% of deaths in hepatocellular carcinoma (HCC) patients. Thus, identification of
novel agents that can downregulate CXCR4 expression and its associated functions have a great potential in the treatment
of metastatic HCC. In the present report, we investigated an anthraquinone derivative, emodin for its ability to affect CXCR4
expression as well as function in HCC cells. We observed that emodin downregulated the expression of CXCR4 in a dose-and
time-dependent manner in HCC cells. Treatment with pharmacological proteasome and lysosomal inhibitors did not have
substantial effect on emodin-induced decrease in CXCR4 expression. When investigated for the molecular mechanism(s), it
was observed that the suppression of CXCR4 expression was due to downregulation of mRNA expression, inhibition of NF-
kB activation, and abrogation of chromatin immunoprecipitation activity. Inhibition of CXCR4 expression by emodin further
correlated with the suppression of CXCL12-induced migration and invasion in HCC cell lines. In addition, emodin treatment
significantly suppressed metastasis to the lungs in an orthotopic HCC mice model and CXCR4 expression in tumor tissues.
Overall, our results show that emodin exerts its anti-metastatic effect through the downregulation of CXCR4 expression and
thus has the potential for the treatment of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is a highly aggressive and
deadly malignancy representing the fifth most common cancer
worldwide and the fourth leading cause of cancer related deaths
worldwide [1,2]. Although surgical resection and use of conven-
tional chemotherapy have slightly improved the outcome in HCC
patients of late, the long-term prognosis remains unsatisfactory
because of its inherent capacity of invasiveness and metastasis.
Chemokine receptors have been reported to be involved in various
aspects of HCC initiation and progression, specifically in
migration, invasion and metastasis [3,4]. Chemokines are a
superfamily of small secreted molecules that consists of 40 ligands
and at least 20 corresponding receptors [5]. Based on the position
of the first two conserved cysteine residues, the chemokines can be
separated into four categories, CXC, CC, C, and CX3C, and
exert their biological effects through selective membrane-bound G
protein-coupled receptors [4,5]. Among the large family of
chemokines and their receptors, the most extensively studied is
CXCR4/CXCL12 signaling cascade, which is expressed by
various types of tumor cells, including, liver [6–9] and plays a
critical role in the inflammatory responses, angiogenesis, tumor
growth, invasion, and metastasis [10–12].
The effects of the CXCR4/CXCL12 axis on HCC are
considered to be multidimensional and it has been implicated in
both the homing of tumor cells to specific organs, as well as the
growth of tumor cells at specific locations, which are most likely
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mediated by the effects of CXCR4 on migration, invasion, and
metastasis [7–9]. For example, Xiang et al., recently showed that
CXCR4 expression significantly correlated and was predictive of
bone metastasis in HCC patients and also decreased overall
median survival [8]. Also it has been found that the nuclear
accumulation of CXCR4 is associated with a higher risk of lymph
node metastasis in HCC [13]. Thus, CXCR4 may not only prove
useful for predicting distant organ metastasis, but may also serve as
a therapeutic target for HCC.
In the present report, we investigated the effect of emodin (1, 3,
8-trihydroxy-6methylanthraquinone), an active component found
in the root and rhizome of Rheum palmatum L. (Polygonaceae) as a
novel regulator of CXCR4 expression and function in HCC.
Although emodin has been previously reported to possess anti-
inflammatory, anti-proliferative, pro-apoptotic and chemopreven-
tive activities in many tumor cell lines and animal models [14–18],
whether emodin can modulate invasion and metastasis in HCC
has not been investigated before. Also, our group is currently
investigating the detailed anticancer mechanisms of emodin in
HCC and has observed that it can cause suppression of signal
transducer and activator of transcription 3 signaling cascade and
enhancement of TNF-related apoptosis-inducing ligand-induced
apoptosis in HCC cells (manuscripts communicated). The present
findings clearly indicate that emodin can downregulate constitu-
tive CXCR4 expression in HCC cells and tissues derived from
orthotopic mice model. This inhibition occurred at the transcrip-
tional level and contributed to the suppression of metastasis in an
orthotopic HCC mice model.
Results
The present study was designed to investigate the effect of
emodin (with structure shown in Fig. 1A) on both CXCR4
expression and function in HCC cells and orthotopic mice model.
Emodin Suppresses the Expression of CXCR4 Protein in
HCC Cells
Several lines of evidence implicate the role of CXCR4 in both
invasion and metastasis in HCC [1,6,7,13]. Hence, we first
investigated the expression level of CXCR4 in four different HCC
cell lines, namely HepG2, Hep3B, PLC/PRF5 and HUH7. As
shown in Fig. 1B, it is clearly evident that CXCR4 is substantially
expressed in all four different HCC cell lines. Because, HER2 has
been shown to induce the expression of CXCR4 in tumor cells
[19], we also analyzed the expression levels of HER2 in these four
HCC cells. However, we found that there is no obvious
relationship between CXCR4 and HER2 expression levels in
HCC cell lines, as HER2 expression level was relatively lower in
Hep3B and PLC/PRF5 cells that showed relatively high
expression levels of CXCR4 (Fig. 1B). Interestingly, only in
HepG2 cells, the expression level of HER2 was quite high and
comparable to CXCR4 levels (Fig.1B). Hence, we first decided to
investigate the effect of emodin on CXCR4 expression in detail in
HepG2 cells. When HepG2 cells were incubated either with
different concentrations of emodin for 6 h or with 50 mM of
emodin for different times, emodin suppressed the expression of
CXCR4 in a dose- (Fig. 1C) and time- (Fig. 1D) dependent
manner. The exposure of cells to 50 mM emodin for 6 h
significantly inhibited the CXCR4 expression as evident by time
kinetics study in Fig. 1D. This downregulation was not due to
decrease in cell viability as approximately 90% of cells were viable
under these conditions (data not shown).
Since HER2 has been reported to regulate the expression of
CXCR4 by stimulating CXCR4 translation and attenuating
CXCR4 degradation [19], we also examined whether emodin
affects CXCR4 expression through the modulation of HER2
expression in HCC cells. For this, HER2-overexpressing HepG2
cells were incubated with different concentrations of emodin for
6 h and then examined for HER2 expression by Western blot
analysis using specific antibodies. We found that HER2
expression was partially affected after emodin treatment in
HepG2cells (Fig. 1E), thus suggesting that downregulation of
CXCR4 expression by emodin may not be completely due to
modulation of HER2 expression. We further found that emodin
also downregulated the expression of both protein (Fig. 1F) and
mRNA (Fig. 1G) for CXCR4 in a time dependent manner in
Hep3B cells, thereby suggesting that the effect of emodin on
CXCR4 expression is not limited to a single HCC cell line.
Downregulation of CXCR4 Expression by Emodin is not
Mediated through its Degradation
Bhandari et al., 2007 have reported previously that CXCR4
undergoes ubiquitination at its lysine residue followed by
degradation [20], therefore we next investigated the possibility
that emodin may enhance the rate of CXCR4 degradation via the
activation of proteasomes. To investigate this, we examined the
ability of ALLN, a proteasome inhibitor, to block emodin -induced
degradation of CXCR4. HepG2 cells were pretreated with ALLN
for 1 h before being treated with emodin. As shown in Fig. 2A,
ALLN had minimal effect on emodin-induced degradation of
CXCR4, suggesting that this is an unlikely basis for the
suppression of CXCR4 expression by emodin. Since CXCR4
has also been shown to undergo ligand-dependent lysosomal
degradation [20], we next investigated the ability of chloroquine, a
lysosomal inhibitor, to block emodin induced degradation of
CXCR4. The cells were pretreated with chloroquine for 1 h
before exposure to emodin. Our results showed that chloroquine
at 200 mM only slightly prevented the degradation of CXCR4
(Fig. 2B), suggesting that this was arguably not the primary
pathway for modulation of CXCR4 expression.
Downregulation of CXCR4 by Emodin Occurs at the
Transcriptional Level
Since emodin did not downregulate CXCR4 expression by
enhancing its degradation in HepG2 cells, we next investigated
whether suppression occurs at the transcriptional level instead.
Cells were treated with emodin for different times and mRNA was
extracted for quantitative real-time PCR analysis. As shown in
Fig. 2C, emodin induced downregulation of CXCR4 mRNA
expression in a time dependent manner, with significant reduction
observed as early as 6 h after exposure.
Emodin Suppresses NF-kB Activation in HCC Cells
The promoter of CXCR4 is known to contain several NF-kB
binding sites [21]. Thus it is possible that emodin may exert its
effect on CXCR4 by suppressing NF-kB activation. The effect of
emodin on TNF-a inducible NF-kB activation in HepG2 cells was
determined using DNA binding assay. We found that treatment
with emodin suppressed NF-kB activation in a time-dependent
manner (Fig. 3A). This result suggests that emodin may
downregulate CXCR4 expression through inhibition of NF-kB
activation. Because, DNA binding alone is not always associated
with NF-kB dependent gene transcription [22], suggesting that
additional regulatory steps are involved. Results of luciferase-based
reporter assay also indicated that emodin inhibited NF-kB
reporter activity significantly in a time-dependent manner in
HepG2 cells (Fig. 3B).
Inhibition of CXCR4 Expression by Emodin in HCC
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Figure 1. Emodin suppresses CXCR4 in HCC cells. A, The chemical structure of emodin. B, Western blot analysis of CXCR4 and HER2 expression
in HCC cells. Whole-cell extracts of HepG2, Hep3B, HUH7, and PLC/PRF5 (30 mg) were resolved on SDS-PAGE gel and probed with anti-CXCR4 and
HER2 antibodies. As a loading control, stripped membrane was probed with b-actin antibody. C, Emodin suppresses CXCR4 levels in a dose-
dependent manner. HepG2 cells (16106) were treated with the indicated concentrations of emodin for 6 h. Whole cell extracts were then prepared,
and 30 mg of protein was resolved on SDS-PAGE, electrotransferred onto nitrocellulose membranes, and probed for CXCR4. The same membrane was
stripped and reprobed with b-actin antibody to show equal protein loading. D, Emodin suppresses CXCR4 levels in a time-dependent manner. HepG2
cells (16106) were treated with 50 mM emodin for the indicated times, after which Western blotting was done as described above. E, Effect of emodin
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Emodin Inhibits Binding of NF-kB to the CXCR4 Promoter
Whether the downregulation of CXCR4 by emodin in Hep3B
cells was due to suppression of NF-kB activation in vivo was
examined by a ChIP assay targeting NF-kB binding in the
CXCR4 promoter. We found that emodin suppressed the NF-kB
binding to the CXCR4 promoter (Fig. 3C) thereby indicating that
emodin inhibits CXCR4 expression by directly attenuating NF-kB
binding to the CXCR4 promoter.
Emodin Suppresses CXCL12-induced HCC Migration and
Invasion
Whether downregulation of CXCR4 by emodin correlated with
HCC migration was examined using an in vitro wound healing
assay. We found that both HepG2 and Hep3B cells migrated
faster under the influence of CXCL12 and this effect was
abolished on treatment with emodin (Figs. 4A and 5A). To
elucidate further the effect on emodin on CXCL12-induced cell
invasion, we also found using an in vitro invasion assay, that
treatment of emodin suppressed CXCL12induced invasion of both
HepG2 and Hep3B cells (Figs. 4B and 5B).
on HER2 expression in HepG2 cells. HepG2 cells (16106) were treated with 50 mM emodin for the indicated times, after which Western blotting for
HER2 was done as described above. The same membrane was stripped and reprobed with b-actin antibody to show equal protein loading. The
representative results of two independent experiments are shown. F, Emodin suppresses expression of CXCR4 protein expression in Hep3B cells. Cells
were incubated with 50 mM emodin for indicated times. Whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies
against CXCR4. The same membrane was stripped and reprobed with b-actin antibody to show equal protein loading. Representative results of two
independent experiments are shown. G, Emodin suppresses expression of CXCR4 mRNA expression in Hep3B cells. Hep3B cells were treated with
50 mM emodin for indicated times. Total RNA was isolated and analyzed by quantitative real time PCR assay as described in Materials and Methods.
GAPDH was shown to equal loading of total RNA. Representative results of two independent experiments are shown.
doi:10.1371/journal.pone.0057015.g001
Figure 2. Emodin suppresses CXCR4 mRNA level in HCC cells. A and B, Emodin suppresses CXCR4, neither by proteasomal nor by lysosomal
degradation. HepG2 cells (16106) were treated with indicated concentrations of ALLN or chloroquine for 1 h at 37uC, followed by treatment of 50 mM
emodin for 6 h. Whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies against CXCR4. The same blots were
stripped and reprobed with b-actin antibody to show equal protein loading. Representative results of two independent experiments are shown. C,
Emodin suppresses the expression of CXCR4 mRNA in HepG2 cells. HepG2 cells were treated with 50mM emodin for the indicated time intervals, after
which cells were harvested after treatment and total RNA samples were extracted. 1mg portions of the respective RNA extracts then proceed for
Reverse Transcription to generate corresponding cDNA. Real time PCR was performed to measure the relative quantities of CXCR4 mRNA using
targeted TaqMan probes, with GAPDH as endogenous control for measurement of equal loading of RNA samples. Results were analyzed using
Sequence Detection Software version 1.3 provided by Applied Biosystems. Relative gene expression was obtained after normalization with
endogenous GAPDH and determination of the difference in threshold cycle (Ct) between treated and untreated cells using 2-DDCt method.
doi:10.1371/journal.pone.0057015.g002
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Emodin Suppresses Lung Metastasis and CXCR4
Expression in HCC Orthotopic Mice Model
We next investigated the ability of emodin to suppress
metastasis in vivo using an orthotopic HCC mice model. Fig. 6A
shows the ex-vivo bioluminescent images of the lungs from all
tumor-bearing mice at euthanasia. All mice developed distant
pulmonary metastasis from the orthotopically implanted
HCCLM3_Luc tumor when the signal-to-background signal ratio
of the primary tumor exceeded 161011 p/s. None of these tumors
was superficially obvious or palpable. The overall metastatic
signals observed in the corn oil-treated mice (1.8 x10763.226106;
n = 7) were significantly higher compared to mice given 25 mg/kg
emodin (8.49610662.566106; n= 6; p= 0.0368) and 50 mg/kg
emodin (9.18610662.166106; n= 8; p= 0.0285) (Fig. 6B), dem-
onstrating emodin treatment could significantly suppressed the
development of lung metastasis.
Furthermore, we also examined whether emodin can inhibit
CXCR4 expression in tumor tissues by Western blot analysis.
Tissue extracts were prepared and probed with anti-CXCR4
antibody. Immunoblot analysis showed that emodin significantly
suppressed the expression of CXCR4 in tumor tissue (Fig. 6C). We
next investigated the effect of emodin on CXCR4 expression in
mice tissues isolated from HCC orthotopic model. As shown in
Fig. 6D, immunohistochemical analysis, showed strong CXCR4
expression in untreated tumor tissues and interestingly, emodin
administered mice showed reduced staining thereby, indicating
that emodin can suppress the expression of CXCR4 in HCC
tissues. In addition, the expression level of CXCR4 in tumor
tissues was also determined by ELISA assay. As shown in Fig. 6E,
a significant decrease in the levels of CXCR4 was observed
indicating emodin suppressed CXCR4 levels. Collectively, all
these data indicate that emodin can modulate CXCR4 expression
and function both in vitro an in vivo in HCC cell lines and mouse
model.
Discussion
The goal of the present study was to determine whether anti-
cancer agent emodin can modulate the expression and function of
CXCR4, a chemokine receptor that has been closely linked with
tumor cell proliferation, invasion, and metastasis. Our results
indicate for the first time that emodin downregulated the
expression of CXCR4 in HCC cells, irrespective of their HER2
status. For example, emodin was found to suppress CXCR4
expression in both high HER2 overexpressing, HepG2 and low
HER2 overexpressing Hep3B cells. Our results also indicated that
downregulation of CXCR4 did not predominantly occur through
proteolytic degradation of the receptor but rather through the
downregulation of the transcript. Furthermore, emodin treatment
led to the downregulation of migration and invasion induced by
the ligand CXCL12 metastasis to the lungs in an orthotopic HCC
mice model and CXCR4 expression in tumor tissues.
The CXCR4 chemokine receptor has been found to be
overexpressed in different tumors, including HCC, breast cancer,
ovarian cancer, glioma, pancreatic cancer, prostate cancer,
melanoma, cervical cancer, colorectal cancer, small-cell lung
carcinoma, acute myeloid leukemia, chronic lymphoblastic leuke-
mia (CLL), B-CLL, and non-Hodgkin’s lymphoma, as compared
to normal cells which show little or no CXCR4 expression [19–
23]. Although it is still unclear, that what leads to the
overexpression of CXCR4 in different tumor cells, previous
reports implicate the involvement of various genetic and epigenetic
factors [23]. PAX3-and PAX7-FKHR gene fusion [24], mutations
in the von Hippel Lindau gene [25], hypoxic conditions in the tumor
microenvironment [26], NF-kB [21], vascular endothelial growth
factor [27], and tumor necrosis factor alpha [28] have all been
found to regulate CXCR4 overexpression in different tumor cells.
Recently, the epidermal growth factor receptor, c-erbB2, and its
encoding gene, HER2/neu, have also been implicated in the
positive regulation of CXCR4 expression at the post-transcrip-
tional level [29,30]. Given that CXCR4 has been linked with the
metastasis, and poor survival in HCC [8], CXCR4 can be
Figure 3. Emodin inhibits TNF-a inducible NF-kB activation in
HepG2 cells. A, HepG2 cells were incubated with 50 mM emodin for
the indicated time points and then stimulated with TNF-a (1 nM) for
24 h. The nuclear extracts were assayed for NF-kB activation by
TransAM p65 transcription factor assay kit. Bars indicate standard error.
* indicates p value ,0.05. B, HepG2 cells were transiently transfected
with an NF-kB luciferase plasmid and co-transfected with b-galactosi-
dase and then treated with 50 mM emodin for the indicated time points
and then stimulated with TNF-a (1 nM) for 24 h. Cell supernatants were
thereafter collected and assayed for luciferase activity as described in
Materials and Methods. Representative results of two independent
experiments are shown. Results are expressed as fold activity over the
activity of the vector control. Bars indicate standard error. * indicates p
value ,0.05; ** indicates p value ,0.001. C, Emodin inhibits binding of
NF-kB to the CXCR4 promoter. Hep3B cells were treated with 50 mM
emodin for indicated time intervals and the proteins were crosslinked
with DNA by formaldehyde and then subjected to ChIP assay using an
anti-p65 antibody with the CXCR4 primer. Reaction products were
resolved by electrophoresis.
doi:10.1371/journal.pone.0057015.g003
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considered as an ideal molecular target for the investigation of
novel therapeutic interventions for the prevention and treatment
of metastatic HCC.
Our results clearly indicate that emodin suppressed CXCR4
expression in both high and low HER2 expressing HCC cells, but
had minimal effect on HER2 expression in HepG2 cells.
Figure 4. Emodin suppresses migration and invasion of HepG2 cells. A, Wound-healing assay was performed for evaluating the inhibitory
effect of emodin on HepG2 cell migration. Confluent monolayers of HepG2 cells were scarred, and repair was monitored microscopically after 12 h of
pre-treatment with emodin (50 mM) before being exposed to 100ng/mL CXCL12 for 24 h. Width of wound was measured at time zero and 24 h of
incubation with and without emodin in the absence or presence of CXCL12. The representative photographs showed the same area at time zero and
after 24 h of incubation. B, HepG2 (26105 cells) were seeded in the top-chamber of the Matrigel. After pre-incubation with or without emodin
(50 mM) for 12 h, transwell chambers were then placed into the wells of a 24-well plate, in which we had added either the basal medium only or basal
medium containing 100 ng/mL CXCL12 for 24 h. After incubation, they were assessed for cell invasion as described in Materials and Methods.
Columns represent percentage of invaded cells; bars, S.E. *indicates p value ,0.05. Representative results of two independent experiments are
shown.
doi:10.1371/journal.pone.0057015.g004
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Thereafter, we decided to investigate the various possible
mechanisms by which emodin can cause downregulation of
CXCR4 expression in HCC cells. One major mechanism
involving the ligand-dependent downregulation of the CXCR4
receptor by lysosomal degradation has been reported previously
[19]. Also, another study has indicated that E3 ubiquitin ligase
atrophin-interacting protein 4 arrestin-2 complex can function on
endosomes to regulate sorting of CXCR4 into the degradative
pathway [20]. Moreover, Subik and coworkers recently reported
that the ubiquitin E3 ligase WWP1 can negatively regulate cell
migration to CXCL12 by limiting CXCR4 degradation to
promote breast cancer metastasis to bone [31]. However, we
found that emodin does not downregulate the CXCR4 expression
entirely through this mechanism and thereby analyzed whether
the inhibition of CXCR4 by this napthoquinone could possibly
occur at the transcriptional level. Indeed, we found that emodin
downregulated the expression of CXCR4 mRNA in HCC cells as
observed by quantitative PCR analysis.
Emodin has been previously reported to downregulate NF-kB
activation in various tumor cells [14]. Therefore, it is possible that
downregulation of CXCR4 by emodin may occur through the
suppression of NF-kB signaling, as binding site for this transcrip-
tion factor has been identified in the proximal region of the
CXCR4 promoter [21]. Indeed, we found that inhibition of
Figure 5. Emodin suppresses migration and invasion of Hep3B cells. A, Wound-healing assay for evaluating the inhibitory effect of emodin
on cell migration. Confluent monolayers of Hep3B cells were scarred, and repair was monitored microscopically after 12 h of pre-treatment with
emodin (50 mM) before being exposed to 100 ng/mL CXCL12 for 24 h. Width of wound was measured at time zero and 24 h of incubation with and
without emodin in the absence or presence of CXCL12. The representative photographs of two independent experiments showed the same area at
time zero and after 24 h of incubation. B, Hep3B (26105 cells) were seeded in the top-chamber of the Matrigel. After pre-incubation with or without
emodin (50 mM) for 12 h, transwell chambers were then placed into the wells of a 24-well plate, in which we had added either the basal medium only
or basal medium containing 100 ng/mL CXCL12 for 24 h. After incubation, the chambers were assessed for cell invasion as described in Materials and
Methods. Columns represent percentage of invaded cells; bars, SE. * indicates p value ,0.05. Representative results of two independent experiments
are shown.
doi:10.1371/journal.pone.0057015.g005
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Figure 6. Emodin suppresses lung metastasis and CXCR4 expression in orthotopic mice model. Spontaneous metastatic model of
human liver cancer cells orthotopically implanted in nude mice. Cubes of HCCLM3_Luc tumor were implanted orthotopically into the liver of female
Balb/c nude mice. Mice were euthanized when the detectable liver tumor signal was .161011 p/s. A, At the time of necropsy, bioluminescent
imaging was employed to monitor signals from lung metastasis. The lung biopsy was imaged to detect metastasis in the lungs. The color bar depicts
Inhibition of CXCR4 Expression by Emodin in HCC
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constitutive NF-kB activation by emodin can be a causative factor
for the downregulation of CXCR4 in HCC cells. Whether
additional molecular mechanism(s) other than suppression of NF-
kB activation are involved in downregulation of CXCR4 by
emodin, cannot currently be confirmed or ruled out. Furthermore,
besides CXCR4, the activation of NF-kB also regulates the
expression of various inflammatory molecules including cycloox-
ygenase-2, matrix metallopeptidase-9, and endothelial-leukocyte
adhesion molecule 1, all of which have been linked with HCC
migration, invasion, and metastasis [32]. Also, since emodin can
inhibit both DNA binding ability and transcriptional activation of
NF-kB, as observed by us, it is possible that emodin can suppress
the expression of other NF-kB regulated genes as well in HCC
cells.
We further investigated the effect of emodin on CXCL12-
induced migration and invasion of HCC cells. We found that pre-
incubation of cells with emodin can also inhibit CXCL12-induced
migration and invasion of both HepG2 and Hep3B cells. This
shows the pivotal role of the CXCR4 receptor in HCC invasion
and the potential of emodin to downregulate the expression or the
activity of CXCR4. However, a part of our results are in
agreement with a recent study by Ok et al. who reported that
emodin indeed can inhibit the migration and invasion of prostate
and lung cancer cells by downregulating the expression of
CXCR4, although the potential in vivo effects of emodin on
metastasis and CXCR4 expression was not investigated by this
group [33].
Using orthotopic HCC model, we also clearly demonstrate
that emodin treatment could significantly suppress the develop-
ment of lung metastasis that in turn correlated with its ability to
downregulate the expression of CXCR4 in vivo as evident by
western blot analysis, immunohistochemistry and ELISA assays.
The results showing that the CXCR4 expression in HCC mice
tissues was suppressed by the administration of emodin is
consistent with the previously reported pivotal role of CXCR4
in regulating the progression, invasion and metastasis in HCC
[7–9]. Taken together, our findings indicate for the first time
that emodin can inhibit metastasis in an orthotopic model
through the modulation of CXCR4 expression in HCC.
Overall, our data shows that emodin can significantly down-
regulate the expression of CXCR4, a key receptor involved in
the crosstalk between tumor cells and its microenvironment,
which contributes to its observed in vivo anti-metastatic effects.
However, additional pre-clinical and clinical studies are needed




A 50 mM solution of emodin (from Aldrich), with purity of
99%, was prepared in DMSO, stored as small aliquots at –20uC,
and then diluted further in cell culture medium as needed. DMSO
(0.1%) was used as vehicle control for all the in vitro experiments.
Tris, glycine, NaCl, SDS, N-Acetyl-L-leucyl-L-leucyl-L-norleuc-
inal (ALLN), chloroquine, and bactin antibody were purchased
from Sigma-Aldrich (St. Louis, MO, USA). DMEM, fetal bovine
serum (FBS), 0.4% trypan blue vital stain, antibiotic-antimycotic
mixture, and HRP-conjugated secondary antibodies were ob-
tained from Invitrogen (Carlsbad, CA, USA). Antibodies against
CXCR4 and HER2 were obtained from Abcam (Cambridge, MA,
USA). CXCL12 was purchased from ProSpec-Tany TechnoGene
Ltd. (Rehovot, Israel).
Cell Lines
Human hepatocellular carcinoma (HCC) cell lines HepG2 and
PLC/PRF5 cells were obtained from American Type Culture
Collection (Manassass, VA). HUH-7 and Hep3B cells were kindly
provided by Prof. Kam Man Hui, National cancer Centre,
Singapore. HepG2, Hep3B, PLC/PRF5, and HUH-7 cells were
cultured in Dulbecco’s Modified Eagle Medium (DMEM)
containing 16antibiotic-antimycotic solution with 10% FBS.
HCCLM3 was a kind gift of Professor Zhao-You Tang at the
Liver Cancer Institute (Zhongshan Hospital, Fudan University,
Shanghai) and have been described previously [34]. HCCLM3
were cultured in high glucose DMEM containing 16antibiotic-
antimycotic solution with 10% FBS.
Western Blot Analysis
Untreated and emodin-treated HCC cells were lysed in lysis
buffer (20 mM Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA
(pH 8.0), 0.1% Triton X-100, 0.01 mg/mL aprotinin, 0.005 mg/
mL leupeptin, 0.4 mM PMSF, and 4 mM NaVO4). HCC tumor
tissues (50 mg/mouse) were minced and incubated on ice for
30 min in 0.5 mL of ice-cold lysis buffer (10% NP-40; 5 M, NaCl;
1 M, HEPES; 0.1 M, EGTA; 0.5 M, EDTA; 0.1 M, PMSF;
0.2 M, sodium orthovanadate; 1 M, NaF; 2 mg/ml, aprotinin;
2mg/ml, leupeptin) and homogenized for 5 min. Lysates were then
spun at 14,000 rpm for 10 min to remove insoluble material and
resolved on a 10% SDS gel and western blotting was done as
described previously [35].
NF-kB Reporter Assay
HepG2 cells were plated in 96-well plates with 16104 cells
per well in 10% FBS containing DMEM. After overnight
incubation, cells were transfected with a NF-kB reporter
plasmid linked to a luciferase gene or with the dominant-
negative IkBa (IkBa-DN) plasmid, cotransfected with b-galac-
tosidase plasmid (Promega, WI). NF-kB luciferase plasmid was
obtained from Stratagene (La Jolla, CA). Transfections were
done according to the manufacturer’s protocols using Fu-
GENEH 6 obtained from Roche, (Indianapolis, IN, USA). At
24 h posttransfection, cells were treated with emodin for the
indicated time points and then washed and lysed in luciferase
lysis buffer (Promega, Madison, WI, USA). Luciferase activity
was measured by Tecan plate reader (Durham, NC) by using a
luciferase assay kit (Promega) and was normalized to b-
galactosidase activity. All luciferase experiments were done in
triplicate and repeated two or more times.
the photon flux (p/s) emitted. #=mouse ID; D= day at necropsy. Lung and liver signals are in p/s unit. B, Comparison of the lung metastasis signals
detected at time of necropsy for the untreated and emodin-treated groups. C, Tumor tissue extracts were prepared as described in Methods. 30 mg of
protein was taken and analyzed by Western blot analysis with antibodies against CXCR4. The same blots were stripped and reprobed with b-actin
antibody to show equal protein loading. D, Immunohistochemical analysis of representative section of tumor tissues stained with anti-CXCR4
antibody demonstrate strong cytoplasmic staining for CXCR4 in the control section and weak cytoplasmic staining in the emodin treated section E,
Emodin decreases CXCR4 levels in tumor tissues. Tumor tissue homogenate was prepared as described in Methods. 150 mg of the tissue supernatant
was taken for ELISA assay. Assay was performed according to manufacturer’s instructions using ELISA kit to determine the levels of CXCR4 in the
control and treated group. Data is represented as Mean 6 SE. * indicates p value ,0.05.
doi:10.1371/journal.pone.0057015.g006
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NF-kB DNA-binding Activity Assay
HepG2 cells were plated in 96-well plates with 16104 cells per
well in 10% FBS containing DMEM. After overnight incubation,
cells were treated with emodin for the indicated time points either
in presence or absence of TNF-a- and NF-kB DNA-binding
activity was analyzed using the TransAM NF-kB p65 transcription
factor assay kit (Active Motif, Carlsbad, CA, USA) as described
previously [35].
RNA Extraction and PCR Analysis
Total RNA isolation was performed using TRIZOLH reagent
(Invitrogen) according to the manufacturer’s instructions and RT-
PCR was performed as described previously [35]. For real time
PCR, 1 mg of total RNA was transcribed to generate cDNA as
described previously [35]. For a 50ml reaction, 10ml of product was
mixed with 16 TaqManH Universal PCR Master mix, 2.5 ml of
206 TaqMan probes for CXCR4, 2.5ml of 206 GAPDH
TaqMan probe as the endogenous control. Relative gene
expression was obtained after normalization with endogenous
GAPDH and determination of the difference in threshold cycle
(Ct) between treated and untreated cells using 22DDCt method.
Primers and probes for human CXCR4, and GAPDH were
purchased as Assays-on-Demand kits (Applied Biosystems).
Chromatin Immunoprecipitation (ChIP) Assay
Hep3B cells were processed for the ChIP assay as per the
protocol described previously [35]. The antibody used for the
ChIP was NF-kB (p65) antibody from Santa Cruz Biotechnology
(SantaCruz, CA, USA). The sequence for human CXCR4 gene
promoter was follows: sense primer, 59-ACAGAGA-
GACGCGTTCCTAG-39 and antisense primer, 59-AGCC-
CAGGGGACCC TGCTG-39. The PCR products were analyzed
on 2% agarose gel electrophoresis and documented.
Wound Healing Assay
HCC cells were treated with emodin as described above. Before
plating the cells, two parallel lines were drawn at the underside of
the wells, to serve as fiducial marks demarcating the wound areas
to be analyzed. Prior to inflicting the wound, the cells should be
fully confluent. The growth medium was aspirated off and
replaced by calcium-free PBS to prevent killing of the cells at
the edge of the wound by exposure to high calcium concentrations
before two parallel scratch wounds were made perpendicular to
the marker lines with a sterile 1000-mL automated pipette tip.
Thereafter, the calcium-free medium was then changed to
medium with or without emodin. After incubation for 12 h with
emodin, the growth medium was then changed to basal medium
with CXCL12. 24 h later, the wounds were observed using bright
field microscopy and multiple images were taken at areas flanking
the intersections of the wound and the marker lines at the start and
end of the experiment. Gap distance of the wound was measured
at three different sites using Photoshop software, and the data were
normalized to the average of the control. Graphs were plotted
against the percentage of migration distance the cells moved
before and after treatment, normalized to control.
Invasion Assay
The in vitro invasion assay was performed using Bio-Coat
Matrigel invasion assay system (BD Biosciences, San Jose, CA), as
described previously [35].
Orthotopic HCC Spontaneous Metastasis Model
All procedures involving animals were reviewed and approved
by the SingHealth Animal Use and Care Committee. Five millions
human HCCLM3 cells expressing firefly luciferase
(HCCLM3_Luc) in 0.05 ml was injected subcutaneously into the
rear flank of 10-week old female Balb/c nude mouse (Biolasco,
Taiwan). When the tumor size reached approximately 1 cm3,
tumor was harvested, cut into 1 mm3 pieces and surgically
implanted in the liver of fresh Balb/c nude mice. Tumor growth
was monitored weekly by bioluminescent imaging using the
IVISTM camera system (Xenogen, Alameda, CA, USA). Mice
were randomized and treatment was started once stably increasing
bioluminescence signals were observed. Mice were given 25 mg/
kg or 50 mg/kg emodin in corn oil 5 days a week by intra-
peritoneal injection. As control, corn oil only was given. Tumor-
bearing mice were euthanized once the tumor signal reached
above 161011 photons per second (p/s). For ex vivo imaging,
150 mg/kg D-luciferin (Xenogen) was injected into the mice
intraperitoneally just before necropsy. Lungs were excised, placed
into tissue culture dish and imaged for 1 min. Regions of interest
in the displayed images were quantified using Living Image
software (Xenogen).
Immunohistochemistry
At the end of treatment period, HCC tumor tissue was fixed
with 10% phosphate buffered formalin, processed and embedded
in paraffin. Tissue sections, 5 micron size, were cut and
deparafinized as described previously [36]. Sections were incu-
bated with primary antibody antiCXCR4 at 1:75 dilution.
Negative control sections were incubated in 2% bovine serum
albumin. Immunohistochemical analysis was performed according
to the manufacturer’s instructions using DAKO LSAB kit. Images
were taken using Olympus BX51 microscope (magnification,
20X).
Enzyme-linked Immunosorbent Assay (ELISA)
The effect of emodin on CXCR4 levels in tumor tissue extracts
was determined using CXCR4 ELISA kit (USCN Life Science
Inc, USA) according to manufacturer instructions. Briefly, tumor
samples were thoroughly rinsed in ice-cold PBS to remove excess
blood, weighed, cut into small pieces and kept on ice. 500 mL of
PBS containing protease inhibitor was added to the tissue
fragments and homogenized using a tissue homogenizer on ice.
The resulting tissue extract was sonicated for 30 seconds and
subjected to two freeze thaw cycle to ensure complete breakdown
of cells. The homogenate was centrifuged for 10 min at 10,0006g.
The supernatant was taken, protein concentration was determined
using Bradford reagent and assayed immediately. 150 mg of the
protein was taken for ELISA assay and the sample CXCR4
concentration was determined by comparing to the standard.
Statistical Analysis
The experiments were carried out in triplicates and repeated
twice. The significance of differences between groups was
evaluated by Student’s t-test and a p value of less than 0.05 was
considered statistically significant.
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